New treatment option for active lupus nephritis!
Clinical trials show that using voclosporin with mycophenolate mofetil is more effective at stopping lupus nephritis from getting worse than mycophenolate mofetil alone. This option is recommended for treating active class 3 to 5 lupus nephritis in adults. The cost-effectiveness estimates are within what NICE considers acceptable for NHS resources.
Recent Posts
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Health as a Strategic Economic Imperative
A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recent EFPIA Guest Blog by Michael Oberreiter frames he...
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gram-Negative Infections
Emblaveo Approved for MDR Gram-Negative Infections
Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avibactam) for financing under Decree-Law No. 97/2015....
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line Therapy
Sacituzumab Govitecan Shows Promise in First-Line TNBC Therapy
Sacituzumab govitecan for TNBC represents a major step forward in treating untreated